Analyst loves Eli Lilly for its potential blockbuster obesity drug — and we do, too – CNBC

  1. Analyst loves Eli Lilly for its potential blockbuster obesity drug — and we do, tooCNBC
  2. Eli Lilly’s valuation is justified when you look at the growth profile, says UBS’ BristowCNBC Television
  3. LLY Stock Nabs Upgrade To Buy As Obesity, Alzheimer’s Catalysts LoomInvestor’s Business Daily
  4. Eli Lilly stock upgraded to Buy on forecast for new diabetes drugYahoo Finance
  5. Lilly could clinch $25B in peak sales of Mounjaro: analystsFiercePharma
  6. View Full Coverage on Google News

.

Leave a Comment

Your email address will not be published.